LUND, SE / ACCESS Newswire / October 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and ...
LUND, SE / ACCESS Newswire / December 7, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and ...
During the first part of the Phase 1/2a study (NCT04752826) the safety, tolerability, and potential signs of efficacy of BI-1808 as a single agent (part A) and in combination with the anti-PD-1 ...
As previously reported, the single agent dose escalation of BI-1910 in the Phase 1 study was completed without any notable adverse events Updated clinical data will be presented at the Society for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results